Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4055 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Piedmont to begin new trial of head lice treatment

In contrast to current treatments that contain insecticides such as lindane, malathion, permethrin and pyrethrins that are neurotoxic to insects, Piedmont’s patented treatment utilizes an insecticide-free, non-neurotoxic formulation.

Roche increases Tamiflu production

The company expects to have the capacity to produce up to 400 million treatments annually by the end of 2006 – an addition of 100 million treatments. Tamiflu

MorphoSys and Daiichi form alliance

Under the agreement, Daiichi Sankyo has committed to start one therapeutic antibody program with MorphoSys and will receive an option for further programs. During the initial two-years, Daiichi

Edison partners universities in research

The collaboration is designed to combine the preclinical biology skills and clinical expertise resident at Columbia and Bologna, with translational and drug development competencies of Edison, with the

Researchers develop diagnostic test for pathogens

Increasing international travel, trafficking in wildlife, political instability, and terrorism have made emerging infectious diseases a global concern. Viral hemorrhagic fevers (VHF) are of specific concern because they

BioMarin and Alliant in licensing deal

Under the terms of the agreement, BioMarin will receive payments and royalties based on the product’s approval, launch and level of sales. BioMarin will retain commercial rights outside

Serono metabolic drug posts positive trial results

Phenylketonuria (PKU) affects approximately 50,000 diagnosed patients in the developed world and is caused by a deficiency of the enzyme phenylalanine hydroxylase which is required for the metabolism